ROCKVILLE, Md. , Sept. 25, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ® Technology Platform, today announced it will participate in the following upcoming investor conferences, which will each be held in a virtual meeting format:
SVB Leerink CybeRx Series: Rare Diseases & Genetic Medicines
Date: Thursday, October 1, 2020
Jefferies Virtual Gene Therapy/Editing Summit
Date: Friday, October 2, 2020
Chardan Virtual 4 th Annual Genetic Medicines Conference
Date: Tuesday, October 6, 2020
Fireside Chat: Tuesday, October 6, 2020 at 10:30 a.m. ET
A live webcast of the Chardan fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com . An archived replay of the fireside chat webcast will be available in the Investors section of REGENXBIO's website for approximately 30 days following the presentation.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
Contacts:
Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
Investors:
Eleanor Barisser, 212-600-1902
eleanor@argotpartners.com
Media:
David Rosen , 212-600-1902
david.rosen@argotpartners.com
View original content: http://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-301138006.html
SOURCE REGENXBIO Inc.